Cambridge Healthtech Institute’s 9th Annual

Clinical and Translational Biomarkers

Enabling Advances in Precision Medicine

June 18-19, 2019


The promise of precision medicine has been driven by the need to accurately predict patient response to therapy while ensuring drug efficacy and safety. Reducing costs and the time required for drug development is also a driving force in the use of biomarkers. Cambridge Healthtech Institute’s 9th Annual Clinical and Translational Biomarkers conference will cover novel biomarker discovery, clinical and analytical biomarker validation, and the role of biomarkers in clinical decision making.

ADVANCES IN BIOMARKER DISCOVERY AND DEVELOPMENT

Have We Progressed in Biomarkers and Diagnostics over the Decade 2008 to 2018?

Abdel B. Halim, PharmD, PhD, DABCC-CC, DABCC-MD, DABCC-Tox, Vice President, Translational Medicine, Biomarkers & Diagnostics, Celldex Therapeutics

Novel LC-MS/MS Approaches from FFPE Tissue Sections for Translational Biomarker Investigations

Mireia Fernandez Ocana, PhD, Global Biomarker Lead, Drug Safety, Pfizer

Overcoming Challenges in Clinical Biomarker Development

Xuemei Zhao, PhD, Senior Principal Scientist, Translational Molecular Biomarkers, Merck Research Labs

BIOMARKERS IN CLINICAL TRIALS

Biomarker-Driven Patient Selection and Outcome Measures in Neurology Trials

Johan Luthman, DDS, PhD, Senior Vice President, Head of Clinical Development, Neurology, Eisai

‘Patient-Centric’ Biomarkers: Utility of Minimally Invasive Sampling in Clinical Trials

Dmitri Mikhailov, PhD, Director & Head, Biomarker Development, Novartis Institutes for BioMedical Research

Business of Fit-for-Purpose for Clinical Trial Biomarker Support

Iman Jilani, PhD, Director, Oncology Clinical Assay Group, Early Development, Pfizer

LIQUID BIOPSY IN PRECISION MEDICINE

ctDNA Utility and Challenges

Carl Barrett, PhD, Vice President, Translational Sciences, Onc iMed, AstraZeneca

Preanalytical Variables in Cell-Free DNA Analysis

Angela Silvestro, MS, Principal Scientist, Novartis Oncology Precision Medicine


For more details on the conference, please contact:
Virginia Maxwell
Senior Associate Producer
Cambridge Healthtech Institute
Phone: 781-972-5436
Email: vmaxwell@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute

781-247-6286
reymael@healthtech.com

Companies L-Z
Joseph Vacca, MS
Director, Business Development
Cambridge Healthtech Institute
781-972-5431
jvacca@healthtech.com